Sildenafil
Product Images NDC 68071-3506

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 68071-3506). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3506 1)

Label for Sildenafil 50mg tablets by NuCare Pharmaceuticals, Inc. The label states 10 tablets per package, with each tablet containing sildenafil citrate equivalent to 50mg sildenafil USP. The tablets are described as oval-shaped, white to off-white, with debossing 'AN 354' on one side. Manufacturer details and storage instructions at controlled temperature 68-77°F are included.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 1)

Chemical structure of the active ingredient Sildenafil, showing the arrangement of various functional groups and atoms including rings, carbon, nitrogen, oxygen, and sulfur atoms typical to this molecule.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 2)

Line graph depicting systolic blood pressure changes (mmHg) over 24 hours post-dose for Sildenafil 100 mg and placebo. The x-axis shows time post dose in hours, while the y-axis represents systolic blood pressure. The graph compares the effects of Sildenafil 100 mg and placebo on systolic blood pressure over time.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 3)

A line graph showing the change in systolic blood pressure (SBP) over time post dose in hours. It compares the effects of Doxazosin plus Placebo and Doxazosin plus Sildenafil 25 mg on SBP changes, with two distinct lines plotted over an 8-hour period.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 4)

A line graph showing change in systolic blood pressure (SBP) over time post dose (hours). Two lines compare Doxazosin + Placebo and Doxazosin + Sildenafil 50 mg, with SBP changes plotted from 0 to 8 hours post dose.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 5)

A line graph comparing blood pressure changes over 8 hours after dosing of Doxazosin combined with Sildenafil 100 mg versus Doxazosin with Placebo. The vertical axis represents blood pressure in mmHg, and the horizontal axis shows time after dosing in hours. Two lines track the changes for each treatment group.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 6)

A line graph showing plasma concentrations (ng/ml) of a commercial tablet formulation of Sildenafil over time post dose in hours. The graph plots plasma concentration on the vertical axis versus time up to 24 hours on the horizontal axis, depicting the drug's absorption and elimination profile after administration.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 7)

Bar chart showing the effect of sildenafil on maintenance of erection by baseline score. The x-axis represents baseline scores from 0 to 5, and the y-axis shows the percentage of patients at endpoint. Multiple bars for each baseline score correspond to different categories ranging from 0 to 5, illustrating patient distribution across these response levels.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 8)

A bar chart titled 'Effect of Placebo on Maintenance of Erection by Baseline Score' showing the percentage of patients at endpoint on the vertical axis and baseline scores from 0 to 5 on the horizontal axis. Different bars represent categories labeled from 0 to 5, indicating various measures or groups corresponding to each baseline score.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 9)

Bar chart showing the percentage of patients reporting improvement across different treatment groups: Placebo (24%), Sildenafil 25 mg (63%), Sildenafil 50 mg (74%), and Sildenafil 100 mg (82%). The x-axis lists treatment groups with sample sizes, and the y-axis shows percentage improvement. An overall treatment p-value of less than 0.0001 is noted at the bottom.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.